AION — Aion Therapeutic Share Price
Last trade - 00:00- CA$6.17m
- CA$7.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.98 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 53.49 | ||
| Price to Sales | 27.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -132.37% | ||
| Return on Equity | n/a | ||
| Operating Margin | -615.82% | ||
Financial Summary
| Year End 30th Apr | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aion Therapeutic Inc. is a Canada-based company, which operates within the health and wellness sector with a diverse portfolio of intellectual property. The Company, through its subsidiary, AI Pharmaceuticals Jamaica Limited, is engaged in research, development and treatment, as well as new therapeutic formulation discovery using data mining and artificial intelligence (AI) techniques. The Company develops healing chemical compounds from medical cannabis in combination with chemical compounds from psychedelic and edible mushrooms to treat conditions, such as cancer, depression, post-traumatic stress disorder (PTSD) and others, as well as opioid and alcohol addiction. The Company is also engaged in offering a water filtration system that incorporates mechanical filtration, membrane filtration, adsorption, silver infection control, ion exchange, and chemical additions into a three-stage water purification solution designed to meet the needs of consumers, business, and industries.
Directors
- Last Annual
- April 30th, 2023
- Last Interim
- January 31st, 2024
- Incorporated
- January 13th, 2011
- Public Since
- February 21st, 2019
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 411,549,269
- Address
- 700 West Georgia Street, Suite 2200, ONTARIO, V7Y 1K8
- Web
- https://www.osoyooscannabis.com/
- Phone
- +1 6045584300
- Auditors
- DNTW Toronto LLP
Upcoming Events for AION
Similar to AION
1933 Industries
Canadian Securities Exchange
1CM
Canadian Securities Exchange
Acreage Holdings
Canadian Securities Exchange
Adastra Holdings
Canadian Securities Exchange
Asia Green Biotechnology
Canadian Securities Exchange
FAQ
As of Today at 19:00 UTC, shares in Aion Therapeutic are trading at CA$0.02. This share price information is delayed by 15 minutes.
Shares in Aion Therapeutic last closed at CA$0.02 and the price had moved by +200% over the past 365 days. In terms of relative price strength the Aion Therapeutic share price has outperformed the Toronto Stock Exchange 300 Composite Index by +180.79% over the past year.
There is no consensus recommendation for this security.
Aion Therapeutic does not currently pay a dividend.
Aion Therapeutic does not currently pay a dividend.
Aion Therapeutic does not currently pay a dividend.
To buy shares in Aion Therapeutic you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.02, shares in Aion Therapeutic had a market capitalisation of CA$6.17m.
Here are the trading details for Aion Therapeutic:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: AION
Based on an overall assessment of its quality, value and momentum Aion Therapeutic is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aion Therapeutic. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -32.53%.
As of the last closing price of CA$0.02, shares in Aion Therapeutic were trading +21.09% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Aion Therapeutic PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Aion Therapeutic's management team is headed by:
- Graham Simmonds - CEO
- Rakesh Malhotra - CFO
- Larry Horwitz - IND
- Sara Irwin - IND